Format

Send to

Choose Destination
J Clin Invest. 2019 Jul 22;129(8):3401-3406. doi: 10.1172/JCI126366. eCollection 2019 Jul 22.

CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.

Author information

1
Department of Medicine.
2
Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA.
3
Division of Rare Cancer Research, National Cancer Center Research Institute, Tokyo, Japan.
4
Cellular and Molecular Pharmacology, UCSF, San Francisco, California, USA.

Abstract

Transcription factor fusion genes create oncoproteins that drive oncogenesis and represent challenging therapeutic targets. Understanding the molecular targets by which such fusion oncoproteins promote malignancy offers an approach to develop rational treatment strategies to improve clinical outcomes. Capicua-double homeobox 4 (CIC-DUX4) is a transcription factor fusion oncoprotein that defines certain undifferentiated round cell sarcomas with high metastatic propensity and poor clinical outcomes. The molecular targets regulated by the CIC-DUX4 oncoprotein that promote this aggressive malignancy remain largely unknown. We demonstrated that increased expression of ETS variant 4 (ETV4) and cyclin E1 (CCNE1) occurs via neomorphic, direct effects of CIC-DUX4 and drives tumor metastasis and survival, respectively. We uncovered a molecular dependence on the CCNE-CDK2 cell cycle complex that renders CIC-DUX4-expressing tumors sensitive to inhibition of the CCNE-CDK2 complex, suggesting a therapeutic strategy for CIC-DUX4-expressing tumors. Our findings highlight a paradigm of functional diversification of transcriptional repertoires controlled by a genetically aberrant transcriptional regulator, with therapeutic implications.

KEYWORDS:

Cancer; Molecular genetics; Oncology

PMID:
31329165
PMCID:
PMC6668665
[Available on 2019-11-01]
DOI:
10.1172/JCI126366
Free full text

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation
Loading ...
Support Center